Evaluating the Use of GLP-1 Receptor Agonists in Wolfram syndrome Patients
This retrospective cohort study of 84 Wolfram syndrome patients found that while GLP-1 receptor agonists are frequently used, they did not significantly improve glycemic control or halt visual decline and were often discontinued due to gastrointestinal side effects, highlighting the need for prospective trials to evaluate their potential as a disease-modifying therapy.